We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Jessica
Welch
jessica.welch@ndcn.ox.ac.uk
Dr
Michele
Hu
michele.hu@ndcn.ox.ac.uk
Dr
Michele
Hu
michele.hu@ndcn.ox.ac.uk
Adriana
Nastasa
adriana.nastasa@ndcn.ox.ac.uk
Extrapyramidal and movement disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder characterised by the motor symptoms of
resting tremor, rigidity, slowness of movement and poor balance. At the time these symptoms first emerge, and the
clinical diagnosis of PD can be made, approximately 70% of the dopaminergic brain cells have already been
irreversibly lost. Early treatment intervention is likely to have the biggest impact on the course of the disease, however
this is hampered by a lack of certainty about the diagnosis in the early stages when motor symptoms first emerge.
The Discovery cohort established in 2010-2015 facilitated the recruitment and longitudinal assessment of 1100 early
PD, 300 control and 300 individuals at-risk of future PD from the Thames Valley over 5 yrs. Individuals are studied at
baseline and longitudinally every 18 months with standardised clinical assessments and blood tests, with the option
of an additional MRI brain scan, lumbar puncture and skin biopsy. The study aim is to develop biomarkers to facilitate
the earlier diagnosis and disease stratification of PD, supported by the strong multidisciplinary program of the Oxford
Parkinson's Disease Centre (OPDC), that has combined basic and clinical research to establish a major research
centre in PD with an international reputation. An additional 5 years of funding to allow assessment of this cohort from
2015-20 was awarded by Parkinson's UK following scientific review, hence the current ethics application.
Moving forward in the second phase of our research program, we will direct our increased knowledge of disease
mechanisms to develop translational research aimed at changing clinical practice. Critically, our new program will
now target the molecular pathways to Parkinson's exploiting new tools (i) to predict the onset of PD in at-risk
individuals (ii) to stratify the progression of PD following diagnosis and (iii) to identify potential targets and treatments
to prevent the development of PD
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
For PD patients, PD relatives, RBD subjects and control subjects: (a) Subject has a severe medical or psychiatric illness that would interfere with completing initial and follow-up assessments (b) Subject has severe mental impairment due to dementia or psychosis such that they lack capacity to make informed decisions (c) Active pregnancy For control subjects: (a) Active participation by a control subject in a clinical drug trial Lumbar Puncture Exclusion Criteria (applicable to all study participants): (a) Treatment with blood thinners, e.g. warfarin (b) Coagulation abnormalities known (c) Coagulopathy or platelet counts <100,000 cells/microL (d) Lumbar spinal surgery within the last 6 months prior to screening, or any lumbar spinal surgery that interferes with anatomy of the intervertebral spaces (e) History of chronic or repeat CSF leakage following previous lumbar puncture(s) (f) Active infectious process MRI exclusion criteria (applicable to all study participants): (a) Pacemakers (b) Electronically, magnetically and mechanically activated implants (c) Metallic splinters in the eye (d) Ferromagnetic haemostatic clips in the central nervous system (CNS) (e) Any other additional exclusionary factors as indicated in the OCMR Imaging Procedures Manual DaTSCAN exclusion criteria (applicable to all study participants): (a) Confirmed pregnancy (b) Use of any concomitant medication that is known or suspected to interact with striatal uptake through direct competition with binding of DaTSCAN to the DAT that could not be discontinued for at least 5 half-lives (these include amphetamine, benztropine, bupropion, cocaine, mazindol, methylphenidate, phentermine and sertraline).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Jessica
Welch
jessica.welch@ndcn.ox.ac.uk
Dr
Michele
Hu
michele.hu@ndcn.ox.ac.uk
Adriana
Nastasa
adriana.nastasa@ndcn.ox.ac.uk
Dr
Michele
Hu
michele.hu@ndcn.ox.ac.uk
The study is sponsored by University of Oxford and funded by PARKINSON'S DISEASE SOCIETY OF THE UNITED KINGDOM .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 30509
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
